8.93
+1.94%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nexstim Oyj
Its shares trade on Nasdaq Helsinki under the ticker NXTMH.HE. It has been listed since 14 November 2014. In the fiscal year to 31 December 2025, it reported revenue of €11.0m and net income of €573,200. At that date it held total assets of €13.2m and shareholders' equity of €4.2m.
Nexstim engages in the provision of medical technology products. The company is headquartered in Helsinki, Etela-Suomen. The company went IPO on 2014-11-14. The company is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 14 Nov 2014
- Employees
- 37
- Website
- nexstim.com ↗
Leadership
Pay as last reported
- Ms. Leena NiemistoChairman of the Board, since 2019
- Mr. Mikko KarvinenChief Executive Officer, Member of the Management Board
- Mr. Joonas JuokslahtiChief Financial Officer, Member of the Management Board
- Ms. Hanna KotolaVice President Legal, Quality and Regulatory Affairs; Member of the Management Team
- Mr. Jarmo LaineVice President, Medical Affairs, Member of the Management Team
- Mr. Gustaf JarnefeltVice President, Research & Development; Member of the Management Team
- Mr. Henri HannulaChief Commercial Officer
- Mr. Martin ForssMember of the Board
- Mr. Timo HildenMember of the Board
- Mr. Tero WeckrothMember of the Board
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nexstim Oyj employs 37 full-time employees in Helsinki, Finland.
- The NBS System provides presurgical mapping for motor and speech cortices using nTMS technology.
- The NBT System is in Phase III clinical trials for stroke therapy in the United States.
Weaknesses
- Nexstim Oyj has only 37 employees, which may limit operational capacity.
- The company's NBT System is still in Phase III clinical trials, requiring further validation.
- Nexstim Oyj has two subsidiaries, Nexstim Inc and Nexstim Germany GmbH, which may increase operational complexity.
Opportunities
- Nexstim Oyj's NBS System is used in over 100 facilities globally for research and therapy.
- The NBT System targets upper limb motor disability in stroke rehabilitation, a significant market need.
- Nexstim Oyj's focus on noninvasive brain stimulation aligns with growing healthcare technology trends.
Threats
- Nexstim Oyj's NBT System is in Phase III clinical trials, which could face regulatory delays.
- The company's reliance on a single product line for stroke therapy poses market risk.
- Nexstim Oyj's small employee count of 37 may hinder rapid market expansion.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.